The abstract is read at the publisher; the summary is JClub's.
MBD4 loss-of-function tumors are linked to strong ATR inhibitor (ceralasertib) hypersensitivity in a TP53-mutant background, with Delta LN_IC50 = -1.07 (95% CI [-1.62, -0.41]).
- Why it matters: DDR defects are often mapped to PARP inhibitor sensitivity by analogy to HRD, but this leaves post-immunotherapy treatment prioritization uncertain for upstream BER glycosylase loss.
- What they did: Using DepMap 24Q2 CRISPR/RNA-seq (n=1,517) and GDSC2 dose-response profiling (n=928), the study restricted MBD4-LOF to truncating/canonical splice-site alleles (21 of 36 lines) and tested drug dependencies with Mann-Whitney U, BH-FDR, and a 5-layer de-confounded synthetic lethality ML engine.
- The result: The framework also supports cytidine analog vulnerability (gemcitabine/5-fluorouracil) and finds no single-agent PARPi sensitization in MBD4-LOF (e.g., talazoparib p2s=0.973), while ranking gemcitabine #1 and ceralasertib #2 and rejecting PARP inhibitors.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.